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Abstract
PTHrP is necessary for the formation of the embryonic mammary gland and, in its absence, the embryonic mammary bud
fails to form the neonatal duct system. In addition, PTHrP is produced by the breast during lactation and contributes to the
regulation of maternal calcium homeostasis during milk production. In this study, we examined the role of PTHrP during
post-natal mammary development. Using a PTHrP-lacZ transgenic mouse, we surveyed the expression of PTHrP in the
developing post-natal mouse mammary gland. We found that PTHrP expression is restricted to the basal cells of the gland
during pubertal development and becomes expressed in milk secreting alveolar cells during pregnancy and lactation. Based
on the previous findings that overexpression of PTHrP in cap and myoepithelial cells inhibited ductal elongation during
puberty, we predicted that ablation of native PTHrP expression in the post-natal gland would result in accelerated ductal
development. To address this hypothesis, we generated two conditional models of PTHrP-deficiency specifically targeted to
the postnatal mammary gland. We used the MMTV-Cre transgene to ablate the floxed PTHrP gene in both luminal and
myoepithelial cells and a tetracycline-regulated K14-tTA;tetO-Cre transgene to target PTHrP expression in just myoepithelial
and cap cells. In both models of PTHrP ablation, we found that mammary development proceeds normally despite the
absence of PTHrP. We conclude that PTHrP signaling is not required for normal ductal or alveolar development.
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Introduction
Mammary development begins during embryogenesis but is
only completed during lactation. Morphogenesis occurs in stages:
a rudimentary duct system is formed before birth; the ductal
system is expanded during puberty; alveolar structures are formed
during pregnancy; and full secretory differentiation is completed at
the beginning of lactation [1,2,3,4]. After weaning, the alveolar
structures involute, but can redevelop with subsequent pregnancies
to support repeated cycles of reproduction. Although mammary
development is well described, the underlying molecular mecha-
nisms that guide ductal and alveolar development are only partly
understood [1,2,3,4]. It has been well established that changes in
the levels of circulating hormones initiate and guide each of the
distinct stages of development noted above. Circulating ovarian
and pituitary hormones act directly on mammary epithelial cells
and also regulate local webs of growth factors and receptors to
orchestrate epithelial-mesenchymal interactions critical to the
integrated morphogenetic responses of the gland [2,3,5,6]. These
interactions between systemic hormones and local growth factor
signaling networks are often deranged during the progression of
breast cancers, so it is helpful to understand the normal effects of
these systems during development in order to better understand
how they go awry in tumors.
Before puberty, the murine mammary duct system consists of
about 10–15 branches limited to that portion of the stromal fat
pad nearest the nipple [2,4,6]. During puberty, under the
influence of hormones, the ducts grow rapidly and directionally
away from the nipple and through the fatty stroma, undergoing a
process of ductal branching morphogenesis that eventually fills the
entire fat pad with mature ducts, which serve as a scaffold upon
which the alveoli form during pregnancy [2,3,6]. Ductal extension
during puberty relies on the formation of highly proliferative,
bulbous structures known as terminal end buds (TEBs) at the tips
of the ducts. TEBs are composed of multiple epithelial cell layers
surrounded by a fibrous stroma and adipocytes [3]. Ductal
extension is completed by about 9 weeks of age, when the primary
ducts have extended to the distal end of the mammary gland fat
pad and the TEBs regress.
Parathyroid hormone-related protein (PTHrP) is a growth
factor that binds to and activates a G protein–coupled receptor
known as the Type 1 PTH/PTHrP receptor (PTHR1) [7].
Disruption of either gene in mice and loss of PTHR1 function in
humans results in the absence of a mammary gland [7,8,9,10,11].
PTHrP is a product of normal embryonic mammary epithelial
cells and the PTHR1 is found on immature mesenchymal cells
located beneath the embryonic epidermis [8,9,10]. PTHrP is
necessary for the formation of specific mammary mesenchyme
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and, in its absence, the embryonic mammary bud fails to form the
neonatal duct system. PTHrP is also produced by mammary
epithelial cells during lactation, where it circulates to increase bone
resorption, liberating skeletal calcium stores that are used for milk
production [12,13].
The PTHrP gene is also expressed in the peripherally located
epithelial cap cells of TEBs during puberty and the PTH1R is
expressed in the stromal cells immediately surrounding TEBs
[14,15]. Overexpression of PTHrP in cap and myoepithelial cells
using the keratin 14 (K14) promoter suggested that PTHrP acts in
a paracrine fashion on stromal cells to slow the rate of ductal
elongation during puberty [14]. PTHrP increased the basal rate of
apoptosis among epithelial cells in TEBs and blocked the ability of
estrogen to stimulate proliferation and decrease apoptosis in these
cells [14]. These data suggested that PTHrP might act as an
endogenous negative regulator of the effects of estrogen on TEBs.
Herein, we report that PTHrP expression is found in the basal cells
of the developing ducts and in the cap cells of terminal end buds
during pubertal development. To address the physiological role of
PTHrP in mammary development during puberty, we generated
two conditional models of PTHrP-deficiency specifically targeted
to the postnatal mammary gland. These mice undergo normal
pubertal and pregnancy-associated mammary development de-
spite the absence of PTHrP, suggesting that PTHrP signaling is
not required for post-natal ductal and alveolar development.
Results
PTHrP expression during mammary gland development
Embryonic deletion of PTHrP results in a lack of ductal
outgrowth due to a failure in mammary mesenchyme specification
[9]. At later stages of development, the functional role of PTHrP is
not clearly defined. In order to begin to study the function of
PTHrP during postnatal development, we first defined the pattern
of PTHrP gene expression during all stages of mammary
development. Transgenic mice in which the b-galactosidase gene
has been knocked into the PTHrP locus provide a sensitive method
for localizing endogenous PTHrP expression by staining for LacZ
activity [16]. Using PTHrP-lacZ knockin mice (PTHrPlacZ), we
defined PTHrP gene expression during embryogenesis, puberty,
pregnancy and lactation. As shown in Figure 1A, lacZ expression
was detected during mammary placode development in epithelial
cells beginning at embryonic day 11.5 (E11.5). PTHrP expression
also extended along a ‘‘tail’’ of epithelial tails adjacent to and
sometimes between developing placodes within the mammary line.
This pattern suggests that PTHrP gene expression is first activated
in cells within the mammary line as they move towards the
developing placodes and into the mammary buds. As embryonic
development progresses, strong PTHrP expression remains re-
stricted to the epithelial cells of the developing buds (Figure 1B),
and the rudimentary ductal tree at birth (Figure 1C–D).
Expression is absent in the adjacent stromal compartment at all
stages of embryonic development.
Postnatal mammary glands are composed of two epithelial cell
types, luminal and myoepithelial [6]. These two cell lineages form
a bi-layered epithelium with the more centrally located luminal
cells surrounded by a continuous layer of myoepithelial cells. The
ducts are, in turn, surrounded by a few layers of peri-ductal
fibroblasts and are embedded within a fatty stroma. Whole-mount
analysis revealed PTHrPlacZ expression to be restricted to the
epithelial cells within the mammary gland during puberty
(Figure 2A–D). PTHrPlacZ expression was observed in the terminal
end buds (TEBs) as well as the subtending ducts (Figure 2A–D).
Histological sections demonstrated that PTHrPlacZ expression
localized to the cap cells as well as to the monolayer of
myoepithelial cells that line the entire duct system (Fig. 2D),
confirming and extending our previous in situ hybidization data
[15]. PTHrPlacZ expression was not detected in the body cells of the
TEBs, the luminal cells of the ducts, the periductal fibroblasts, or
the stromal adipocytes.
During pregnancy, the mammary epithelium expands dramat-
ically as alveolar structures form at the end of small terminal
ductules that develop from the pre-existing ducts [1,3,6]. Alveolar
structures are specialized for milk production and it is thought that
they arise from multipotent progenitor cells that can give rise to
myoepithelial cells, ductal cells and alveolar cells [17]. During
pregnancy, expression of PTHrP is seen in the myoepithelial cells
of the ducts and in the developing alveolar cells and alveoli
(Figure 2E–G). After pregnancy ends and lactation ensues, PTHrP
expression is also evident in the milk secreting, alveolar epithelial
cells (Figure 2H–J). It is well documented that these cells secrete
large amounts of PTHrP into milk [12,18]. The Xgal staining
during postnatal development is consistent with RT-PCR data
confirming that PTHrP mRNA is expressed at low levels
throughout puberty and until the later stages of pregnancy. At
the onset of lactation, levels increase and then return to baseline
levels with involution (Figure 2K).
Mammary-Specific Deletion of PTHrP Does Not Interfere
with the Initial Stages of Mammary Ductal Outgrowth
Previous studies in our lab demonstrated that overexpression of
PTHrP in myoepithelial cells inhibits ductal elongation during
puberty by blocking the ability of estrogen to increase proliferation
and decrease apoptosis in terminal end buds (TEBs) [14,19]. In
order to determine whether these results reflected the function of
endogenous PTHrP during puberty, we disrupted PTHrP
Figure 1. PTHrP expression during embryogenesis. LacZ staining of PTHrP+/lacZ embryos at (A) E11, (B) E12, (C) E15.5 and (D) birth. (A) At E11,
b-galactosidase staining was observed in the mammary placodes but not the surrounding mesenchyme. (B) By E12.5, intense staining was observed
in all five buds. Interestingly, lacZ positive ‘‘tails’’ were observed from each bud (double arrowhead) (B, C). Single arrowheads indicate mammary
placodes and buds. (D) PTHrPlacZ expression remains restricted to the mammary epithelial cells throughout embryonic and neonatal development.
doi:10.1371/journal.pone.0027278.g001
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signaling during pubertal development. Given that PTHrP2/2
animals die at birth and have no mammary glands [11], we
conditionally deleted the PTHrP gene postnatally, after embryonic
mammary development was completed. We used the MMTV-
Cre, line D mice, which express Cre recombinase in both luminal
epithelial and myoepithelial cells, including the body and cap cells
of TEBs, beginning at the onset of puberty [20]. We confirmed
transgene specificity by breeding MMTV-Cre mice to ROSA26R
(R26R) mice (Figure 3A–C) [21]. b-galactosidase staining of whole
mammary glands shows heterogeneous expression of the MMTV-
Cre transgene during puberty, demonstrating that recombination is
not 100% efficient [20]. Therefore, in order to maximally reduce
local PTHrP levels, the MMTV-Cre transgene was bred onto a
compound heterozygous PTHrPlox/lacZ background, with one floxed
PTHrP allele and one PTHrPlacZ allele. MMTV-Cre;PTHrPlox/lacZ
(MMTV-CKO) mice revealed that disruption of both PTHrP
alleles had no effect on the initial mammary outgrowth (Figure 3D,
and data not shown). Ductal extension was assessed morphomet-
rically in MMTV-CKO and control mice (MMTV-Cre and
PTHrPlacZ). As shown in Figure 3F, there were no significant
differences in the degree of ductal extension of the glands. To
ensure that the absence of a mammary gland phenotype was not
due to the lack of efficient Cre-mediated PTHrP deletion in the
mammary gland, we performed quantitative RT-PCR on whole
mammary tissues from virgin control and MMTV-CKO animals
(Figure 3E). These analyses demonstrated appropriate reduction of
PTHrP mRNA in the MMTV-CKO mammary glands.
Disruption of PTHrP in Myoepithelial Cells Does Not Alter
Mammary Ductal Development
Given our data demonstrating that PTHrP is expressed by
myoepithelial cells and given the potential heterogeneous
expression of the MMTV-Cre transgene in these cells during
puberty, we also specifically deleted the PTHrP gene from
myoepithelial cells in a temporally regulated fashion. Myoepithe-
lial and luminal markers are both expressed in all embryonic
mammary epithelial cells [9]. Therefore, in order to avoid
targeting the embryonic mammary buds, we used a tetracycline-
regulated system to initiate Cre expression in myoepithelial cells
only after birth using bitransgenic K14-tTA;tetO-Cre mice
(Figure 4A–B) to generate K14-tTA;tetO-Cre;PTHrPlox/lacZ mice
(K14-CKO mice) [14]. The K14 promoter is strongly expressed in
the basal cells of the gland and in the cap cells of TEBs, coinciding
with the pattern of PTHrP expression as seen in Figure 2. Unlike
the MMTV promoter, the K14 promoter drives uniform Cre
recombinase expression in all myoepithelial cells during puberty as
documented in K14-tTA;tetO-Cre;R26R mice (Figure 4A–B). As
shown in Figure 4D, PTHrP mRNA expression was efficiently
reduced in the mammary glands using this strategy. However, as
with the previous approach, whole-mount analysis from K14-
CKO animals revealed that disruption of one or both PTHrP
alleles had no effect on the initial mammary outgrowth (Figure 4C,
and data not shown). Ductal extension during puberty was normal
in the K14-CKO mice (Figure 4C&E).
Figure 2. PTHrP expression during postnatal mammary gland development. (A) At the onset of puberty (3 weeks), PTHrPlacZ expression is
seen throughout the ductal tree. (B) As development ensues, –mount Xgal staining is evident in the ducts and TEBs at 5 weeks, specifically in the
myoepitheial cells and the cap cells (C). By 8 weeks, when TEBs have regressed, LacZ expression is restricted to myoepithelial cells in the ducts (D).
During late pregnancy (E–G), LacZ expression is seen in the ducts and is also evident in the developing alveoli. During lactation (H–J), LacZ is
expression is seen in the milk secreting cells. High levels of PTHrPlacZ staining remain in the ducts and the alveoli during lactation. (K) Developmental
survey of PTHrP mRNA expression in whole mammary glands as measured by qRT-PCR. PTHrP mRNA is expressed at low levels in whole mammary
glands throughout virgin postnatal development and throughout pregnancy. At the onset of lactation, PTHrP levels increase, and at involution return
to virgin levels. wks =weeks; P = pregnancy day; L = lactation day; I = involution day. Relative expression: 5 weeks = 1. H&E staining (G, J).
doi:10.1371/journal.pone.0027278.g002
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Ablation of Endogenous PTHrP has no Effect on TEB Cell
Turnover
Previous experiments had demonstrated that overexpression of
PTHrP in cap and myoepithelial cells blunted the effects of
exogenous hormones on cellular proliferation and apoptosis within
the TEBs, raising the possibility that endogenous PTHrP might
normally act to modulate the effects of steroid hormones on TEBs
during puberty [14]. Therefore, we predicted reciprocal changes
in TEB cell turnover in the absence of PTHrP expression (i.e.
enhanced proliferation and reduced apoptosis). We studied mice
during early puberty (5 weeks of age) at baseline and after 48 h of
treatment with exogenous estrogen and progesterone. Cell
proliferation and apoptosis were quantified using EdU (5-
ethynyl-29-deoxyuridine) incorporation and TUNEL staining,
respectively (Figure 5 and data not shown). At baseline, 18% of
epithelial cells in wild-type TEBs incorporated EdU. Hormone
treatment increased TEB proliferation such that 24% of epithelial
cells within TEBs were labeled. As shown in Figure 5A, ablation of
PTHrP did not affect either baseline or hormone-treated rates of
proliferation within the TEBs; there were no differences between
wild-type mice and MMTV-CKO or K14-CKO mutants. Similar
results were seen for measurements of apoptosis (Figure 5B). In
TEBs from WT mice, 3% of epithelial cells were TUNEL-positive
at baseline and 2.4% of the cells were TUNEL-positive after
hormone treatment. There were no significant differences in the
rate of apoptosis in TEBs at baseline or in response to hormone
treatment in either MMTV-CKO or K14-CKO mice as
compared to controls.
Ablation of Endogenous PTHrP has no Effect on
Mammary Epithelial Cell Lineage
Deletion of the PTHrP gene from embryonic mammary
epithelial cells results in reversion of these cells to an epidermal
phenotype. Given the specific expression of PTHrP in myoepithe-
lial cells, we next asked whether PTHrP was needed to maintain
the basal lineage in postnatal epithelial ducts. In order to assess
lineage specification, we stained mammary glands in both PTHrP
conditional mutants using antibodies against K14 and p63, which
Figure 3. MMTV-Cre deletion of PTHrP in the mammary gland does not impair ductal development. (A) MMTV-Cre activity is
heterogeneous in the pubertal gland. Whole-mount Xgal staining of a 5 week old gland. Sections of stained glands demonstrating that luminal and
myoepithelial cells in the ducts (C), as well as body and cap cells of TEBs (B) are targeted for recombination. (D) Whole-mounts of mammary glands
from MMTV-cre and MMTV-cre;PTHrPlox/lacZ mammary glands at 5 weeks of age. (E) PTHrP mRNA expression is decreased in MMTV-cre;PTHrPlox/lacZ
mammary glands. (F) Ductal outgrowth was measured in Control (n = 6) and MMTV-cre;PTHrPlox/lacZ (n = 12) as % of fat pad filled.
doi:10.1371/journal.pone.0027278.g003
PTHrP during Postnatal Mammary Development
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27278
recognize cap cells and myoepithelial cells [14,22], and gata3 and
K18, which identify body and ductal luminal cells [23]. As shown
in Figure 6 (and data not shown), loss of PTHrP did not appear to
affect the overall bilayered architecture of the ducts or the relative
locations of luminal and myoepithelial cells in either conditional
knockout model.
PTHrP is not required for Terminal Differentiation of
Alveolar Epithelial Cells
The PTHrP gene is expressed during pregnancy in alveolar
epithelial cells (Figure 2E). We have previously demonstrated that
PTHrP deletion during late pregnancy and lactation had no effect
on alveolar terminal differentiation [12]. Nevertheless, we next
Figure 4. K14-tTA;tetO-Cre deletion of PTHrP in the mammary gland does not impair ductal development. K14-tTA;tetO-Cre activity is
specific to the myoepithelial cells of the ducts and the cap cells of TEBs (A, B). (A) Whole-mount Xgal staining of a 4 week old gland. (B) Section of
stained gland demonstrating that myoepithelial cells are targeted for recombination in the ducts. (C) Whole-mounts of mammary glands from K14-
tTA;tetO-Cre and K14-tTA;tetO-Cre;PTHrPlox/lacZ mammary glands at 5 weeks of age. (E) PTHrP mRNA expression is decreased in K14-tTA;tetO-
Cre;PTHrPlox/lacZ mammary glands. (F) Ductal outgrowth was measured in Control (n = 4) and K14-tTA;tetO-Cre;PTHrPlox/lacZ (n = 6) as % of fat pad filled.
doi:10.1371/journal.pone.0027278.g004
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examined whether deletion of PTHrP during pubertal develop-
ment might affect alveolar development. Whole-mount analysis
and histological examination revealed normal alveolar develop-
ment on day 18 of pregnancy in both conditional knockout models
of PTHrP deficiency (Figure 7A–F). In addition, histological
analysis of lactating glands demonstrated normal alveolar
differentiation with milk production. Both conditional mutant
strains were able to sustain pups throughout lactation. We did not
observe any weight differences between pups from MMTV-CKO,
K14-CKO or control mothers (data not shown). Finally, no
detectable defects in alveolar development were present even after
multiple round of pregnancy and lactation.
Discussion
PTHrP has important functions during embryonic breast
development and during lactation. In the embryo, PTHrP is
produced by mammary epithelial cells and it interacts with the
PTHR1 on surrounding mesenchymal cells to support proper
mammary mesenchyme differentiation and outgrowth of the
mammary bud [4,9,11]. During lactation, PTHrP is produced by
mammary epithelial cells and is secreted both into milk and into
the maternal circulation, where it regulates systemic calcium and
bone metabolism during lactation and contributes to the
mobilization of calcium for milk production [12,13]. PTHrP also
contributes to the pathophysiology of breast cancer through its
actions on tumor cells themselves, on the tumor microenvironment
and on bone cells to promote the development of osteolytic bone
metastases [24,25,26,27]. Thus, PTHrP is intimately involved in
the regulation of breast development, breast physiology and breast
cancer pathophysiology. In this report, we examined whether
PTHrP is also important for the development of the postnatal
mammary gland.
We first examined the expression of PTHrP. Previous studies
using in situ hybridization had suggested that PTHrP was expressed
within the cap cells of TEBs during puberty [15]. For the current
studies, we made use of a mouse in which the b-galactosidase gene
was knocked into the PTHrP gene locus in order to improve the
sensitivity and spatial resolution of detecting PTHrP expression
[16]. Importantly, our studies confirm the expression of PTHrP
within epithelial cells of the embryonic mammary bud as well as
demonstrate PTHrP gene expression within segments of the
mammary line, especially between buds 2 and 3, and buds 4 and
5. We confirmed that PTHrP is expressed within cap cells of the
TEBs, but also now demonstrate that PTHrP is expressed within
the mature myoepithelial cells in the adult mammary gland during
puberty and throughout the reproductive cycle. These findings are
consistent with previous reports of PTHrP expression exclusively in
basal cells isolated from both human and mouse mammary glands
[28,29]. The PTHrP gene is not expressed in luminal or alveolar
epithelial cells until pregnancy, when lacZ expression was detected
within the developing alveolar epithelial cells. Importantly, PTHrP
is expressed only in mammary epithelial cells; we did not detect its
expression in stromal cells within the mammary fat pad at any
time. These data demonstrate that, after embryogenesis, the
PTHrP gene is expressed only by myoepithelial/cap cells until
Figure 5. Effects of PTHrP deletion on cell turnover in terminal end buds during puberty. (A) End bud cell proliferation in 5-week-old mice
as defined by the percentage of epithelial cells incorporating EdU within TEBs of control, K14-tTA;tetO-Cre;PTHrPlox/lacZ and MMTV Cre;PTHrPlox/lacZ
mice. (B) Apoptosis was measured by TUNEL staining in the TEBs of control, K14-tTA;tetO-Cre;PTHrPlox/lacZ and MMTV Cre;PTHrPlox/lacZ mice. Red bars
represent the baseline rates of proliferation and apoptosis in 5-week-old placebo-treated mice and blue bars represent rates of proliferation and
apoptosis in 5-week-old mice treated with exogenous estradiol and progesterone for 48 h. EdU incorporation was significantly greater in each group
of mice treated with hormones. There were no differences in the response to hormones in control mice as compared to the two types of CKO mice.
There were no differences in apoptosis among control or CKO mice at baseline versus treated with hormones.
doi:10.1371/journal.pone.0027278.g005
Figure 6. Cell lineage is not disrupted by PTHrP deletion in the mammary gland. Expression of the luminal marker, Gata3 and myoepithelial
marker, K14, showed normal mammary gland architecture in both PTHrP MMTV-CKO (C) and K14-CKO (D) as compared to controls (B). (A) IgG control
staining with secondary antibodies.
doi:10.1371/journal.pone.0027278.g006
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27278
pregnancy and lactation, when alveolar epithelial cells also
produce PTHrP.
The expression of PTHrP in cap and myoepithelial cells in close
proximity to the expression of the PTHR1, which is expressed on
stromal cells, suggests that PTHrP might regulate epithelial/
mesenchymal interactions important for ductal extension and
branching. In fact, overexpressing PTHrP in cap and myoepithe-
lial cells using the keratin 14 promoter impaired ductal elongation
by altering TEB cell proliferation and apoptosis in response to
estrogen and progesterone [14,30]. Overexpression of PTHrP also
impaired ductal side-branching in this model [14,30]. Therefore,
we expected that disruption of the PTHrP gene in mammary
epithelial cells would result in a reciprocal phenotype of
accelerated ductal elongation and increased ductal side-branching.
In contrast, MMTV-Cre/PTHrPlox/lacZ mice had normal rates of
ductal elongation and a normal mammary ductal branching
pattern. Additionally, they had normal rates of TEB proliferation
and apoptosis, both at baseline and in response to exogenous
hormones. This was also the case when we disrupted the PTHrP
gene specifically within cap and myoepithelial cells using
tetracycline-regulated bitransgenic expression of Cre recombinase.
K14-tTA;tetO-Cre;PTHrPlox/lacZ mice also had normal ductal
extension and branching as well as normal TEB cell proliferation
and apoptosis. Both models of conditional PTHrP gene disruption
also displayed normal alveolar development during pregnancy and
both types of mice lactated normally (data not shown). Therefore,
it appears that PTHrP expression is not necessary for post-natal
mammary development.
It is not clear why disruption of the PTHrP gene had no effect
on development of the gland given the effects of PTHrP
overexpression on ductal morphogenesis. There are two main
possibilities. First, it is possible that the spatial or temporal pattern
of PTHrP gene disruption was insufficient to eliminate PTHrP
function entirely. While the expression of Cre is somewhat
heterogeneous in the MMTV-Cre mice, the expression of Cre in
myoepithelial and cap cells is very uniform as measured by the
ability to activate lacZ expression when these transgenes were bred
onto an R26R reporter mouse (see Figure 4). Furthermore, RT-
PCR analysis of PTHrP mRNA expression in whole mammary
glands documented effective reductions of PTHrP mRNA
expression (Figure 3E and 4D). Thus, a technical explanation
for our findings is unlikely. Instead, we believe that while PTHrP
contributes to the regulation of ductal morphogenesis, its functions
are likely redundant and other signaling systems are able to
compensate for its loss. This does not necessarily mean that
PTHrP is unimportant in mammary epithelial cells or that the
K14-PTHrP overexpression phenotype is an artifact. In fact, since
PTHrP levels are often upregulated in breast cancer cells, the
Figure 7. Loss of PTHrP has no Effect on Alveolar Development. Whole-mount analysis and histological H&E sections of control (A, D, G, J),
MMTV-CKO (B,E,H,K) and K14-CKO (C,F,I,L) mice during late pregnancy (A–F) and lactation (G–L).
doi:10.1371/journal.pone.0027278.g007
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results of PTHrP overexpression in the mammary gland may shed
light on its effects on tumor cells. In various studies, a higher level
of PTHrP expression has been shown to be associated with either
worse or better outcome in patients with breast cancer [31,32].
Likewise, PTHrP appears to inhibit tumor formation in the
MMTV-Neu transgenic model [26], but to promote tumor
formation in the MMTV-polyoma middle T (MMTV-PyMT)
transgenic model [33]. Therefore, depending on the context,
upregulation of PTHrP expression may have differing effects on
the biology of breast cancer. While normal epithelial cells do not
express the PTHR1 gene, breast cancer cells often do. In addition,
PTHrP can traffic to the nucleus and exert effects on cell
proliferation and survival [27,34]. As a result, autocrine and/or
intracrine PTHrP signaling may affect breast cells in different ways
depending on cell lineage or stage of transformation. Overexpres-
sion models will be necessary to sort out these issues.
In summary, we find that the PTHrP gene is expressed in
myoepithelial and cap cells during post-natal mammary develop-
ment. During pregnancy and lactation, the gene is also expressed
by the secretory alveolar cells. Disruption of the PTHrP gene in all
mammary epithelial cells using the MMTV-Cre transgene or only
in myoepithelial and cap cells using a bitransgenic K14-tTA;tetO-
Cre system, results in no discernable developmental phenotype. We
conclude that PTHrP signaling is not required for post-natal
mammary development.
Materials and Methods
Mouse strains and breeding
MMTV-Cre (line D), tetO-Cre and ROSA26R mice were
purchased from Jackson Laboratories [20]. K14-tTA transgenic
mice were previously generated in our laboratory [14]. PTHrPlacZ
knockin mice were a kind gift from Arthur Broadus [16].
PTHrPlox/lox mice have been described elsewhere [35]. All animals
were outcrossed more than 10 generations and maintained on a
CD1 background (Charles River Laboratories, Wilmington,
Massachusetts, USA). TetO-Cre transgene expression was sup-
pressed by feeding all pregnant bitransgenic mice 150 mg/ml
tetracycline hydrochloride (Roche, Indianapolis, IN, USA) in 5%
sucrose water until birth. All animal experimentation was
conducted in accord with accepted standards of humane animal
care and approved by the Yale IACUC. All experiments
performed were approved in advance by Yale University’s
Institutional Animal Care and Use Committee (protocol #07834).
ß-Galactosidase assay
ß-galactosidase activity was measured in embryonic and adult
mammary tissue as previously described [14].
RNA isolation and RT-PCR
Mammary glands were excised from mice, flash frozen in liquid
nitrogen and total RNA was isolated using TRIzol (Invitrogen,
Carlsbad, CA) as per the manufacturers’ instructions. Contami-
nating DNA was removed using the RNeasy Minikit and DNase 1
treatment (QIAGEN, Inc., Valencia, CA). Two-step quantitative
real-time-PCR was performed using the High Capacity cDNA
archive kit (Applied Biosystems, Foster City, CA) and the Full-
Velocity SYBR-Green QPCR Master Mix kit (Stratagene, La
Jolla, CA) in the Opticon 2 DNA Engine (MJ Research, Waltham,
MA). The relative expression levels were determined using the
comparative 22DDCT method. Glyceraldehyde-3-phosphate dehy-
drogenase was the endogenous reference gene, and the average
22DDCT of the samples from virgin mice served as a calibrator
sample to which all individual samples were normalized. Each
sample was run in triplicate. The following primers were used:
mouse glyceraldehyde-3-phosphate dehydrogenase, forward, 59-
CGTCCCGTAGACAAAAATGGT-39 and reverse, 59-TCAAT-
GAAGGGGTCGTTGAT-39; mouse PTHrP, forward 59-TTC-
AGCAGTGGAGTGTCCTG-39 and reverse, 59-TTGCCCTT-
GTCATGCAGTAG-39.
Whole-mount analysis and Tissue Processing
Whole-mount analysis was performed on mammary tissue as
previously described [19]. Briefly, the no. 4 inguinal mammary
glands were removed and mounted on a microscope slide. The
tissue was fixed in acid ethanol for 1 h at room temperature,
washed in 70% ethanol and distilled water and incubated in
carmine aluminum stain (0.2% carmine, 0.5% aluminum
potassium sulfate) overnight at room temperature. After staining,
the mammary glands were dehydrated through graded ethanol
and defatted in acetone and toluene before being mounted under
glass coverslips using Permount (Fisher Scientific, Fair Lawn, NJ,
USA). Histomorphometry was performed on whole mounts and
the following parameters were measured: total duct length was
measured from the nipple region to the leading edge of the most
distal end bud; the percentage of fat pad penetration was
calculated by dividing the total duct length by the distance from
the nipple region to the most distal aspect of the fatty stroma.
For light microscopy, mammary tissue was fixed in 4%
paraformaldehyde, embedded in paraffin and sectioned at 5 mm
for hematoxylin & eosin (H&E) staining or immunohistochemistry.
Hormone Treatment and Immunohistochemistry
Five-week-old mice were injected (i.p.) with an aqueous solution
of estradiol (24 mg/day) and progesterone (1.2 mg/day) for 2 days
before injection of EdU. Control mice were injected with PBS
[19]. EdU (Invitrogen) was injected 2 hrs before the animals were
sacrificed, after which the no. 4 inguinal mammary glands were
harvested, fixed in 4% paraformaldehyde overnight, washed in
70% ethanol, embedded in paraffin and sectioned at 5 mm. The
sections were then deparaffinized, rehydrated through graded
ethanol to distilled water and put in pressure cooker for 1 minute
in 10 mM sodium citrate buffer. Sections were then processed for
EdU Click-It and immunofluorescence for the lineage markers,
K14, p63, gata3, K18. Fifteen TEBs from a total of five mice per
genotype were counted for each experimental condition. Rates of
TEB proliferation and apoptosis were calculated by dividing the
number of EdU positive nuclei by the total number of nuclei
within five TEBs from each of five animals for each genotype.
Statistics
The differences of the mean values between PTHrP mutant and
control groups were compared using an unpaired t test. All t tests
were two-tailed. All statistical analyses were carried out using
Graph Pad Prism 4.0 for Windows (Graph-Pad Software, San
Diego, CA).
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